Viswanath Reddy Belum1, Giselle de Barros Silva2, Mariana Tosello Laloni2, Kathryn Ciccolini1, Shari B Goldfarb3, Larry Norton3, Nancy T Sklarin3, Mario E Lacouture4. 1. Dermatology Service, Memorial Sloan Kettering Cancer Center, 60th Street Outpatient Center, 16 East 60th St., Suite 407, Room 4312, New York, NY, USA. 2. Centro Paulista de Oncologia, Sao Paulo, Brazil. 3. Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Dermatology Service, Memorial Sloan Kettering Cancer Center, 60th Street Outpatient Center, 16 East 60th St., Suite 407, Room 4312, New York, NY, USA. lacoutum@mskcc.org.
Abstract
INTRODUCTION: The use of scalp cooling for the prevention of chemotherapy-induced alopecia (CIA) is increasing. Cold caps are placed onto the hair-bearing areas of the scalp for varying time periods before, during, and after cytotoxic chemotherapy. Although not yet reported, improper application procedures could result in adverse events (AEs). At present, there are no evidence-based scalp cooling protocols, and there is no regulatory oversight of their use. OBJECTIVE: To report the occurrence of cold thermal injury (frostbite) on the scalp, following the use of cold caps for the prevention of CIA. MATERIALS AND METHODS: We identified four patients who developed cold thermal injuries on the scalp following the application of cold caps. Medical records were analyzed to retrieve the demographic and clinical characteristics. RESULTS: The cold thermal injuries in our patients were grade 1/2 in severity and improved with topical interventions and interruption of cold cap use, although grade 1 persistent alopecia ensued in 3 patients. The true incidence of such injuries in this setting, however, remains unknown. CONCLUSIONS: Cold thermal injuries are likely infrequent and preventable AEs that may result from improper device application procedures during cold cap use. Although these untoward events are usually mild to moderate in severity, the potential occurrence of long-term sequelae (e.g., permanent alopecia and scarring) or the need to discontinue cold cap use, are not known. Prospective studies are needed to further elucidate the risk and standardize healthcare delivery methods, and to improve patient/supportive/healthcare provider education.
INTRODUCTION: The use of scalp cooling for the prevention of chemotherapy-induced alopecia (CIA) is increasing. Cold caps are placed onto the hair-bearing areas of the scalp for varying time periods before, during, and after cytotoxic chemotherapy. Although not yet reported, improper application procedures could result in adverse events (AEs). At present, there are no evidence-based scalp cooling protocols, and there is no regulatory oversight of their use. OBJECTIVE: To report the occurrence of cold thermal injury (frostbite) on the scalp, following the use of cold caps for the prevention of CIA. MATERIALS AND METHODS: We identified four patients who developed cold thermal injuries on the scalp following the application of cold caps. Medical records were analyzed to retrieve the demographic and clinical characteristics. RESULTS: The cold thermal injuries in our patients were grade 1/2 in severity and improved with topical interventions and interruption of cold cap use, although grade 1 persistent alopecia ensued in 3 patients. The true incidence of such injuries in this setting, however, remains unknown. CONCLUSIONS: Cold thermal injuries are likely infrequent and preventable AEs that may result from improper device application procedures during cold cap use. Although these untoward events are usually mild to moderate in severity, the potential occurrence of long-term sequelae (e.g., permanent alopecia and scarring) or the need to discontinue cold cap use, are not known. Prospective studies are needed to further elucidate the risk and standardize healthcare delivery methods, and to improve patient/supportive/healthcare provider education.
Authors: Lauren J Auerbach; Michael G Galvez; Brittney K De Clerck; Jason Glotzbach; Mackenzie R Wehner; Edward I Chang; Geoffrey C Gurtner; Paul S Auerbach Journal: Wilderness Environ Med Date: 2013-03-06 Impact factor: 1.518
Authors: Ole Goertz; Stefan Baerreiter; Andrej Ring; Birger Jettkant; Tobias Hirsch; Adrien Daigeler; Hans U Steinau; Stefan Langer Journal: J Surg Res Date: 2009-08-11 Impact factor: 2.192
Authors: J P Heggers; M C Robson; K Manavalen; M D Weingarten; J M Carethers; J A Boertman; D J Smith; R J Sachs Journal: Ann Emerg Med Date: 1987-09 Impact factor: 5.721
Authors: Joanne M Shaw; Jane O'Brien; Susan Chua; Richard De Boer; Rachel Dear; Nicholas Murray; Fran Boyle Journal: Support Care Cancer Date: 2017-08-29 Impact factor: 3.603
Authors: V V Shah; T C Wikramanayake; G M DelCanto; C van den Hurk; S Wu; M E Lacouture; J J Jimenez Journal: J Eur Acad Dermatol Venereol Date: 2017-11-24 Impact factor: 6.166
Authors: Amanda Graul-Conroy; Margo Hoover-Regan; Kenneth B DeSantes; Paul M Sondel; Natalie S Callander; Walter L Longo; William E Fahl Journal: Integr Cancer Sci Ther Date: 2018-11-29